22. Antitumor effect of CAR-T cells on Human Leukemia Lympho B xenograft NODscid Mice
Main Article Content
Abstract
The study aims to evaluate the antitumor effects of CAR-T in Human Leukemia lympho B xenograft NODscid Mice. Mice were injected with a single dose of 106 Daudi Luci+ cells into the peritoneal cavity. After 3 days, 50 mice were divided into treatment groups using CAR-T cells and the control group using PBMC. The anticancer effects of CAR-T were evaluated by assessing the survival time and rate as well as Luciferase activity in the blood. Luciferase activity in the blood of mice in the treatment groups was lower than that in the control group (p < 0.01). The survival rate of the treated mice group was 90% while the control group was 40%. The survival time in CAR-T groups was higher than that in the control group (p < 0.05). We suggest that CAR-T cells have antitumor effect on Human Leukemia xenograft NODscid Mice.
Article Details
Keywords
CAR-T, Daudi, Luciferase, NODscid
References
2. Judith F, Steuber C, Poplack D. Acute lymphoblastic leukemia. Princile and Practice of Pediattric Oncology. 2005.
3. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. Jan 2009;46(1):52-63.
4. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood cancer journal. Jun 30 2017;7(6):e577. doi:10.1038/bcj.2017.53
5. Bui KC, Ho VH, Nguyen HH, et al. X-ray-irradiated K562 feeder cells for expansion of functional CAR-T cells. Biochem Biophys Rep. Mar 2023;33:101399. doi:10.1016/j.bbrep.2022.101399
6. Nguyen HH, Bui KC, Nguyen TML, et al. The safety of CAR-T cells and PD-1 antibody combination on an experimental model. Biochem Biophys Res Commun. Mar 15 2023;649:25-31. doi:10.1016/j.bbrc.2023.01.096
7. Vallera DA, Chen H, Sicheneder AR, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leukemia research. Sep 2009;33(9):1233-42. doi:10.1016/j.leukres.2009.02.006
8. Verma MK, Clemens J, Burzenski L, et al. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. Journal of immunological methods. Jul 2017;446:47-53. doi:10.1016/j.jim.2017.03.021
9. Vuist WM, v Buitenen F, de Rie MA, et al. Potentiation by interleukin 2 of Burkitt’s lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Res. Jul 15 1989;49(14):3783-8.
10. Dobrenkov K, Olszewska M, Likar Y, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Jul 2008;49(7):1162-70. doi:10.2967/jnumed.107.047324
11. Keller AF, Gravel M, Kriz J. Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia. Aug 1 2009;57(10):1130-42. doi:10.1002/glia.20836
12. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. Sep 15 2007;13(18 Pt 1):5426-35. doi:10.1158/1078-0432.Ccr-07-0674
13. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. Feb 14 2013;121(7):1165-74. doi:10.1182/blood-2012-06-438002
14. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. Nov 15 2006;66(22):10995-1004. doi:10.1158/0008-5472.Can-06-0160